The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 2 of 5 of this archive, newest first.
A proper account of an operation that existed, and of what closing it cost.
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The evidence base is thin and the document says so, which is to its credit.
None of what this piece asks for is commercially sensitive, and all of it is already known to whoever released the batch.
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the sessions, and from the two hours afterwards.
The route did not close because of a rule about peptides.
The route did not close because of a rule about peptides.
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The observation that closes a facility is rarely the dramatic one.
The document is four pages. Three of them are about dates.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
A proper account of an operation that existed, and of what closing it cost.
The evidence base is thin and the document says so, which is to its credit.
Follow the resin, not the catalogue.
Efficacy was never the question in this appraisal. Duration of treatment was.
Every degradation pathway accelerates by orders of magnitude on reconstitution, because the solvent that lyophilisation removed is the reagent most of them need.
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
The evidence base is thin and the document says so, which is to its credit.
A proper account of an operation that existed, and of what closing it cost.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
Follow the resin, not the catalogue.
The masking phenomenon known as low endotoxin recovery means a formulation can return a clean result while containing endotoxin the assay cannot see.
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
A reminder that a purity figure is the output of a method, and that methods differ.
Efficacy was never the question in this appraisal. Duration of treatment was.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The evidence base is thin and the document says so, which is to its credit.
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.